eHealth program for managing persistent pain after breast cancer treatment
Effectiveness of an eHealth Self-management Support Program for Persistent Pain After Breast Cancer Treatment
This study tests if an online program using a chatbot can help people with ongoing pain after breast cancer treatment manage their pain better than regular care or in-person rehab.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 270 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Universiteit Antwerpen Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Antwerp and 1 other locations) |
| Trial ID | NCT06308029 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of an eHealth self-management support program designed for individuals experiencing persistent pain following breast cancer treatment. It compares this program to usual care and a comprehensive face-to-face rehabilitation program, focusing on pain-related disability and other biopsychosocial factors. The innovative program utilizes a chatbot format to deliver pain science education and encourage physical activity, aiming to empower patients with self-management skills. The study seeks to determine if this digital approach can provide timely support and reduce barriers to effective pain management.
Who should consider this trial
Good fit: Ideal candidates are breast cancer survivors who have completed their primary treatment and experience persistent pain that interferes with daily activities.
Not a fit: Patients who are mentally or physically unable to participate, lack access to a digital device, or do not speak or understand Dutch may not benefit from this study.
Why it matters
Potential benefit: If successful, this program could significantly improve pain management and quality of life for breast cancer survivors experiencing persistent pain.
How similar studies have performed: Other studies have shown promise in using digital health interventions for pain management, suggesting potential success for this innovative approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria * Patients (men and women) with primary breast cancer and with unilateral or bilateral axillary surgery (Axillary Lymph Node Dissection or Sentinel Node Biopsy); * Be non-metastatic and have finished their primary treatment with a curative intent at least 3 months prior to study participation; * Adjuvant hormonal therapy and immunotherapy form the exception to the rule are tolerated; * Presence of self-reported persistent pain in the last 3 months that interferes with daily activities (yes/no) Exclusion criteria * Can not participate during the entire study period; * Mentally or physically unable to participate in the study; * Previous participation in a pain science education program. * No acces to a digital device * Do not speak/understand Dutch
Where this trial is running
Antwerp and 1 other locations
- Universiteit Antwerpen — Antwerp, Belgium (Recruiting)
- KU Leuven — Leuven, Belgium (Recruiting)
Study contacts
- Principal investigator: An De Groef, PhD — Universiteit Antwerpen
- Study coordinator: An De Groef, PhD
- Email: an.degroef@uantwerpen.be
- Phone: 003216342171
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.